Trial Profile
A Phase 1, Double-blind, Four Period Crossover Study to Investigate the Effects of Pomalidomide (CC 4047) on the QT Interval in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Moxifloxacin
- Indications Graft-versus-host disease; Multiple myeloma; Myelofibrosis; Pancreatic cancer; Prostate cancer; Sarcoma; Sickle cell anaemia; Small cell lung cancer; Systemic scleroderma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Dec 2013 New trial record